- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Benitec Biopharma Executes Research Collaboration with Nant Capital
Benitec Biopharma Limited (ASX:BLT,NASDAQ:BNTC,NASDAQ:BNTCW) has executed a Research Collaboration Agreement with Nant Capital, and has initiated work on two new oncology pipeline programs. As quoted in the press release: Under the terms of the executed Research Collaboration Agreement, Benitec has taken control of the clinical development of BB-401, a recombinant DNA construct that produces an …
Benitec Biopharma Limited (ASX:BLT,NASDAQ:BNTC,NASDAQ:BNTCW) has executed a Research Collaboration Agreement with Nant Capital, and has initiated work on two new oncology pipeline programs.
As quoted in the press release:
Under the terms of the executed Research Collaboration Agreement, Benitec has taken control of the
clinical development of BB-401, a recombinant DNA construct that produces an antisense RNA with
specificity against Epidermal Growth Factor Receptor (EGFR). This clinically validated molecular target
is overexpressed in up to 90% of all HNSCC. According to GlobalData (Head and Neck Squamous Cell
Carcinoma – Opportunity Analysis and Forecast to 2024, February 2016), approximately 64,000 new
patients will be diagnosed annually in the US with HNSCC and 50% of the patients are expected to
develop recurrent or metastatic disease, with approximately 13,000 annual deaths expected in the US
from HNSCC.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.